Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
As ongoing studies continue to evaluate its long-term efficacy and safety, retatrutides potential to transform obesity and diabetes therapy becomes increasingly clear
Semaglutide, an injectable glucagon-like peptide-1 receptor agonist, has shown promise in reducing cardiovascular events, but its exact mechanism of benefit remains unknown
People are shifting to every other week dosing to reduce the monthly expenses of semaglutide, reduce the severity of side effects, and maintain weight loss and metabolic benefits of semaglutide in the maintenance phase
Obesity occurrence was higher in adults aged 4059 (46.4%) than in people aged 2039 (35.5%) and 60 and older (38.9%)
Important safety information: Wegovy (semaglutide) and Mounjaro (tirzepatide) are prescription-only medications for managing obesity and, in the case of Mounjaro, also type 2 diabetes
US$ 22.72
US$ 24.61
:max_bytes(150000):strip_icc()/GettyImages-1393287140-1a0a64aa9b8f4abc85356e41c0f799a2.jpg)
US$ 23.53
US$ 27.01
US$ 24.47
